Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at Benzinga’s inaugural Global SmallCap Conference on Tuesday, December 8, 2020 at 4:30 pm ET. Investors interested in viewing Annovis Bio’s presentation may register with free access here for the two-day
BERWYN, Pa., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Annovis, Inc. Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at Benzinga’s inaugural Global SmallCap Conference on Tuesday, December 8, 2020 at 4:30 pm ET.
Investors interested in viewing Annovis Bio’s presentation may register with free access here for the two-day conference which takes place virtually from December 8-9, 2020.
During the presentation, Dr. Maccecchini will discuss the Company’s unique approach to AD and other neurodegenerative diseases, current pipeline, and upcoming milestones, including expected publication of data from its current Phase 2a studies in AD and PD.
About Benzinga
Benzinga is a leading financial media company dedicated to making information easier to consume. Benzinga’s news desk is constantly breaking stories and moving billions of dollars of market capitalization through its real-time news tool, Benzinga Pro. Benzinga’s original content is syndicated to 70 partner websites including Yahoo! Finance MSN, CNNMoney, Fox Business and MarketWatch.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and have commenced a second Phase 2a study in AD and PD patients. For more information on Annovis, please visit the company’s website: www.annovisbio.com.
Investor Relations:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com
SOURCE: Annovis Bio, Inc.
